Most Active InvestorsFind investorsBlogPricing
Start for free
Start for free
AC

Acuta Capital Partners

North America, California, United States, Belmont

Description

Acuta Capital Partners is a venture capital firm.

Investor Profile

Acuta Capital Partners has backed more than 22 startups, with 3 new investments in the last 12 months alone. The firm has led 2 rounds, about 9% of its total and boasts 17 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Post Ipo Equity, Series B, Series C rounds (top funding stages).
  • Majority of deals are located in United States, Ireland.
  • Strong thematic focus on Biotechnology, Health Care, Biopharma.

Stage Focus

  • Post Ipo Equity (64%)
  • Series B (18%)
  • Series C (14%)
  • Series Unknown (5%)

Country Focus

  • United States (91%)
  • Ireland (9%)

Industry Focus

  • Biotechnology
  • Health Care
  • Biopharma
  • Life Science
  • Oncology
  • Therapeutics
  • Pharmaceutical
  • Medical Device
  • Manufacturing
  • Medical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Acuta Capital Partners frequently co-invest with?

Surveyor Capital
Surveyor Capital
North America, Illinois, United States, Chicago
Co-Investments: 6
CA
Cormorant Asset Management
North America, Massachusetts, United States, Boston
Co-Investments: 6
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners
North America, California, United States, Palo Alto
Co-Investments: 9
RTW Investments
RTW Investments
North America, New York, United States, New York
Co-Investments: 6
RA Capital Management
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 10
KC
Co-Investments: 6
Avoro Capital Advisors
Avoro Capital Advisors
North America, New York, United States, New York
Co-Investments: 6
Vivo Capital
Vivo Capital
North America, California, United States, Palo Alto
Co-Investments: 8
Logos Capital
Logos Capital
North America, California, United States, San Francisco
Co-Investments: 10
Janus Henderson Investors
Janus Henderson Investors
Europe, England, United Kingdom, London
Co-Investments: 5

What are some of recent deals done by Acuta Capital Partners?

Surrozen

South San Francisco, California, United States

Surrozen is a biopharmaceutical that focuses on unlocking the body’s regenerative power to treat injury and disease.

BiotechnologyEmergency MedicineHealth Care
Post Ipo EquityMar 24, 2025
Amount Raised: $175,000,000
Aadi Bioscience

Pacific Palisades, California, United States

Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.

BiopharmaBiotechnologyLife ScienceOncology
Post Ipo EquityMar 4, 2025
Amount Raised: $100,000,000
Aadi Bioscience

Pacific Palisades, California, United States

Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.

BiopharmaBiotechnologyLife ScienceOncology
Post Ipo EquityDec 20, 2024
Amount Raised: $100,000,000
Enliven Therapeutics

Boulder, Colorado, United States

Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.

BiotechnologyLife ScienceOncologyTherapeutics
Post Ipo EquityMar 19, 2024
Amount Raised: $90,000,000
Ocular Therapeutix

Bedford, Massachusetts, United States

Ocular Therapeutix develops and commercializes ophthalmic therapeutic products by using hydrogel technology.

BiotechnologyHealth CareMedical Device
Post Ipo EquityFeb 22, 2024
Amount Raised: $325,000,000
Tourmaline Bio

New York, New York, United States

Tourmaline Bio is a clinical biotechnology company developing transformative medicines to dramatically improve and prevent immune diseases.

BiotechnologyClinical TrialsTherapeutics
Post Ipo EquityOct 19, 2023
Amount Raised: $75,000,000
Taysha Gene Therapies

Dallas, Texas, United States

Taysha Gene Therapies develops treatments to eradicate severe and life-threatening monogenic diseases of the central nervous system.

BiotechnologyGeneticsLife Science
Post Ipo EquityAug 14, 2023
Amount Raised: $150,000,000
BioAtla

San Diego, California, United States

BioAtla develops safer, more effective drugs for cancer using a proprietary next-generation antibody discovery and evolution platform.

BiotechnologyHealth CareMedical
Post Ipo EquityNov 4, 2022
Amount Raised: $65,000,000
Aadi Bioscience

Pacific Palisades, California, United States

Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.

BiopharmaBiotechnologyLife ScienceOncology
Post Ipo EquitySep 22, 2022
Amount Raised: $72,500,000
Ventyx Biosciences

Encinitas, California, United States

Ventyx is a biopharmaceutical company focused on advancing oral therapies for patients living with autoimmune and inflammatory disorders.

BiopharmaBiotechnology
Post Ipo EquitySep 19, 2022
Amount Raised: $176,600,000

Find More Investors Like Acuta Capital Partners

Discover similar investors in our database and build your perfect investor list.

post_ipo_equity InvestorsInvestors in BelmontBrowse All InvestorsTop Investors

Need help with your fundraising strategy?Read our fundraising guides

Decorative background shape
Decorative background shape

Ready to Raise Capital?

Founders in our network have raised from Y Combinator, Sequoia, a16z, and more. You could be next.

Find investors

Pages

Most Active Investors Find InvestorsNewsletterPricing

Free tools

Pre-Money and Post-Money Valuation Calculator

Investors By Location

San FranciscoNew York CityBostonLos AngelesChicagoLondonParisIndiaSingaporeTel Aviv

Investors By Stage

Angel InvestorsPre-Seed InvestorsSeed InvestorsSeries A InvestorsSeries B InvestorsSeries C InvestorsSeries D Investors
Acuta Capital Partners | Pipeseed